1 Endocrinology, Department of, Abdominal Centre, Rigshospitalet, The Capital Region of Denmark2 Department of Clinical Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; email@example.com Renal Clinical Development and.4 Renal Clinical Development and.5 Renal Clinical Development and.6 Data and Statistical Sciences, AbbVie, North Chicago, Illinois;7 Renal Clinical Development and.8 Salvador Zubiran National Medical Science and Nutrition Institute, Mexico City, Mexico;9 Division of Nephrology, University of Utah Health Sciences Center, Salt Lake City, Utah;10 Department of Clinical Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands;11 Okayama University Graduate School of Medicine, Okayama, Japan;12 George Institute for Global Health, University of Sydney, Sydney, Australia;13 Astellas Global Pharma Development, Inc., Northbrook, Illinois;14 Azienda Ospedaliera Papa Giovanni XXIII and IRCCS-Instituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy;15 Sunnybrook Health Sciences Center, Toronto, Ontario, Canada;16 University of Texas17 Kings College
Despite optimal treatment, including renin-angiotensin system (RAS) inhibitors, patients with type 2 diabetic nephropathy have high cardiorenal morbidity and mortality related to residual albuminuria. We evaluated whether or not atrasentan, a selective endothelin A receptor antagonist, further reduces albuminuria when administered concomitantly with maximum tolerated labeled doses of RAS inhibitors. We enrolled 211 patients with type 2 diabetes, urine albumin/creatinine ratios of 300-3500 mg/g, and eGFRs of 30-75 ml/min per 1.73 m(2) in two identically designed, parallel, multinational, double-blind studies. Participants were randomized to placebo (n=50) or to 0.75 mg/d (n=78) or 1.25 mg/d (n=83) atrasentan for 12 weeks. Compared with placebo, 0.75 mg and 1.25 mg atrasentan reduced urine albumin/creatinine ratios by an average of 35% and 38% (95% confidence intervals of 24 to 45 and 28 to 47, respectively) and reduced albuminuria≥30% in 51% and 55% of participants, respectively. eGFR and office BP measurements did not change, whereas 24-hour systolic and diastolic BP, LDL cholesterol, and triglyceride levels decreased significantly in both treatment groups. Use of atrasentan was associated with a significant increase in weight and a reduction in hemoglobin, but rates of peripheral edema, heart failure, or other side effects did not differ between groups. However, more patients treated with 1.25 mg/d atrasentan discontinued due to adverse events. After stopping atrasentan for 30 days, measured parameters returned to pretreatment levels. In conclusion, atrasentan reduced albuminuria and improved BP and lipid spectrum with manageable fluid overload-related adverse events in patients with type 2 diabetic nephropathy receiving RAS inhibitors.
Journal of the American Society of Nephrology : Jasn, 2014, Vol 25, Issue 5, p. 1083-93